We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02877173
Recruitment Status : Recruiting
First Posted : August 24, 2016
Last Update Posted : March 10, 2017
Sponsor:
Information provided by (Responsible Party):
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Brief Summary:
A phase II,randomized,double-blind,multi-doses,positive drug parallel controlled,multi-center clinical trial to evaluate initially the efficacy and safety of alprostadil liposomes for injection in the treatment of atherosclerotic occlusive disease of the lower extremities.

Condition or disease Intervention/treatment Phase
Arteriosclerosis Obliterans Drug: Alprostadil Liposomes for Injection Drug: Alprostadil Injection Phase 2

Detailed Description:

This is a phase 2 dose-finding study evaluating initially the efficacy and safety of alprostadil liposomes for injection in the treatment of atherosclerotic occlusive disease of the lower extremities at different dose strengths.The total duration of subject participation will be approximately 5 weeks,consisting of a 2-week run-in period,3-week treatment and safety follow-up period.

Subjects will sign the informed consent form(ICF) at a screening visit and will be assigned a subject identifier.Subjects meeting all inclusion/exclusion criteria and who have successfully completed all protocol procedures at screening will enter the 2-week run-in.Following the 2-week run-in period,eligible subjects will be randomized(1:1:1:1) to one of the following double-blind treatment groups:

Group A : Alprostadil Liposomes for Injection at low dose:20ug,once a day(QD); Group B : Alprostadil Liposomes for Injection at medium dose:40ug,QD Group C : Alprostadil Liposomes for Injection at high dose:60ug,QD Group D(Positive Control Group) : Alprostadil Injection:10ug,QD All treatments will be delivered by intravenously guttae.A subject will be consider to have completed the study when they have completed all phase of the study including run-in,randomization,the randomized treatment and efficacy and safety follow-up phase.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities—A Phase II Multi-center Randomised Controlled Trial
Study Start Date : August 2016
Estimated Primary Completion Date : July 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Alprostadil
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Alprostadil Liposomes for Injection
Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
Drug: Alprostadil Liposomes for Injection
3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
Other Name: No other names
Active Comparator: Alprostadil Injection
Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
Drug: Alprostadil Injection
Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
Other Name: No other names



Primary Outcome Measures :
  1. Change from baseline in distance of asymptomatic disease and claudication after 3 weeks of treatment. [ Time Frame: After 3 weeks of treatment ]
    Unit of distance of asymptomatic disease and claudication:meters


Secondary Outcome Measures :
  1. Change from baseline in maximun distance of claudication after 3 weeks of treatment. [ Time Frame: After 3 weeks of treatment ]
    Unit of maximun distance of claudication :meters

  2. Change from baseline in distance of asymptomatic disease and claudication and in maximum distance of claudication after 2 weeks of treatment. [ Time Frame: After 2 weeks of treatment ]
    Unit of distance of asymptomatic disease and claudication:meters

  3. The proportion of patients to treatment failure. [ Time Frame: After 3 weeks of treatment ]
    The treatment failure is defined as arteriosclerosis obliterans(ASO) exacerbation that has necessary to change chemotherapy or have interventional operation.

  4. Incidence of Adverse Events(AEs) [ Time Frame: over 3 weeks of treatment ]

    The safety endpoints for this study include:

    1. AEs
    2. Vital Sign Measurements
    3. Physical examination
    4. Clinical Laboratory Evaluations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • An established clinical history of Atherosclerotic Occlusive Disease of the Lower Extremities in accordance with the definition by Chinese Medical Association(2015).
  • Age>40
  • Atherosclerotic Occlusive Disease of the Lower Extremities diagnosis
  • Arterial ischemia of the lower extremities pulsation has been weakened or disappeared.
  • Ankle brachial index(ABI) less than or equal to 0.9
  • Diagnosis of artery stenosis or occlusion with imaging tests,including Doppler ultrasonography,CT angiogram(CTA),magnetic resonance angiography (MRA) or digital subtraction angiography(DSA) within 1 month prior to Screening.
  • Fontaine stage classification:Stage II
  • Distance of asymptomatic disease and claudication between 50m to 800m(The treadmill setting:pace at 3 km/h,incline at 12%).Subjects have intermittent claudication twice within 1 week prior to enrollment visit(Baseline is defined as the first measurement.Change from baseline in P-values less than or equal to 25%).
  • Age:80 years old or younger.
  • Intermittent claudication has been in stable condition in the last 6 months.And there was no history of exacerbations within 3 months prior to enrollment visit.
  • Informed Consent:A signed and dated written informed consent prior to study participation.

Exclusion Criteria:

  • Subjects who have cardiac disease including caradiac failure,arrhythmias,coronary disease,mitral or aortic stenosis.Subjects with a recent history of myocardial infarction within the past 6 months are to be excluded.
  • Subjects who have pneumonedema,pulmonary infiltrates,interstitial pneumonia,severe chronic obstructive airway disorders or respiratory insufficiency confirmed by clinical examination.
  • Liver:Subjects with abnormal liver function tests defined as aspartate aminotransferase(AST) or alanine aminotransferase(ALT) greater than equal to 1.5 times upper limit of normal,as well as a diagnosis of primary liver disease will be excluded.
  • Renal:Subjects with abnormal kidney function tests defined as Creatinine clearance rate(SCr) greater than or equal to upper limit of normal.
  • Clinically Uncontrolled Hypertension:Subjects who have clinically significant uncontrolled hypertension(Systolic blood pressure:greater than or equal to 180mmHg;Or diastolic blood pressure:greater than or equal to 110mmHg).
  • Ankle systolic pressure is less than or equal to 50mmHg.
  • Subjects with affected limbs surgery or endovascular treatment within 3 months prior to Screening.Subjects who received Prostanoids within the past 1 week are to be excluded.
  • Subjects who received walking rehabilitation training successfully within the past 6 months.
  • Subjects with a diagnosis of other diseases such as lower limb joint disorder,spinal lesions,neuropathy,serious lung and heart conditions which may impact intermittent claudication will be excluded.
  • Subjects who have inflammation of the vascular disease including Takayasu's arteritis,edema perivascular.
  • Subjects with active peptic ulcerease or bleeding tendency will be excluded.
  • Glaucoma:Subjects with a diagnosis of glaucoma or high intraocular pressure will be excluded.
  • Subjects who are medically unable to withhold their vasodilator including naftidrofuryl,pentoxy,buflomedil or cilostazol will be excluded.
  • Subjects who received any powerful analgesic within 1 month perior to Screening.
  • Subjects with a history of psychiatric disease or Alzheimer's Disease.
  • Cancer:Subjects with a diagnosis of cancer will be excluded.
  • Drug Allergy:Subjects who have a history of any componet of Alprostadil Injection.
  • Previous Participation:Subjects who were previously enrolled in any clinical trial within 1 month period to Screening.
  • Pregnancy:Women who are pregnant or lactating or women of childbearing potential who are not using an acceptable method of contraception.
  • Subjects,who in the opinion of the Investigator,will not be fit for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02877173


Contacts
Contact: Yongquan Gu 010-83198605

Locations
China
Xuanwu Hospital Capital Medical University Recruiting
Beijing, China, 100034
Principal Investigator: Yongquan Gu         
Sponsors and Collaborators
Guangzhou Yipinhong Pharmaceutical CO.,LTD
Investigators
Study Chair: Yongquan Gu Xuanwu Hospital, Beijing
Principal Investigator: Xiangchen Dai Tianjing Medical University General Hospital
Principal Investigator: Bonan Lv Hebei General Hospital
Principal Investigator: Jun Zhao Shanghai Sixth People Hospital
Principal Investigator: Jichun Zhao West China Hospital
Principal Investigator: Dan Liu Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Principal Investigator: Haofu Wang The Affiliated Hospital of Qingdao University
Principal Investigator: Gang Zhao First Affiliated Hospital of Heilongjiang Chinese Medicine University
Principal Investigator: Weiguang Guo Second Affiliated Hospital of Heilongjiang University of Chinese Medicine
Principal Investigator: Qi Wang First Hospital of Jilin University
Principal Investigator: Xiwei Zhang The First Affiliated Hospital with Nanjing Medical University

Responsible Party: Guangzhou Yipinhong Pharmaceutical CO.,LTD
ClinicalTrials.gov Identifier: NCT02877173     History of Changes
Other Study ID Numbers: YPH-ZZTP-L01
First Posted: August 24, 2016    Key Record Dates
Last Update Posted: March 10, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Guangzhou Yipinhong Pharmaceutical CO.,LTD:
Arteriosclerosis Obliterans
Atherosclerotic Occlusive Disease of the Lower Extremities
Intermittent Claudication

Additional relevant MeSH terms:
Arteriosclerosis
Arteriosclerosis Obliterans
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Alprostadil
Platelet Aggregation Inhibitors
Vasodilator Agents
Urological Agents